Sinomenine hydrochloride inhibits human hepatocellular carcinoma cell growth in vitro and in vivo: Involvement of cell cycle arrest and apoptosis induction

International Journal of Oncology

Volumn 42, Issue 1, 2013, Pages 229-238

  Lu, Xin Lan ^a   Zeng, Jin ^a   Chen, Yu Le ^a   He, Peng Mei ^a   Wen, Mai Xia ^a   Ren, Mu Dan ^a   Hu, Ya Nan ^a   Lu, Gui Fang ^a   He, Shui Xiang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Caspase; Cell cycle arrest; Hepatocellular carcinoma; P21 WAF1 Cip1; Sinomenine hydrochloride; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 10; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOCHROME C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; SINOMENINE HYDROCHLORIDE; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASPASES; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOCHROMES C; FLOW CYTOMETRY; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MORPHINANS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 84873659641     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1704     Document Type: Article

References (44)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Lencioni R, Chen XP, Dagher L and Venook AP: Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 15: 42-52, 2010.
3. Rahbari NN, Mehrabi A, Mollberg NM, et al: Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253: 453-469, 2011.
4. Kishi Y, Hasegawa K, Sugawara Y and Kokudo N: Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol 2011: 728103, 2011.
5. Yamasaki H: Pharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutum. Acta Med Okayama 30: 1-20, 1976.
6. Liu L, Riese J, Resch K and Kaever V: Impairment of macrophage eicosanoid and nitric oxide production by an alkaloid from Sinomenium acutum. Arzneimittelforschung 44: 1223-1226, 1994.
7. Liu L, Resch K and Kaever V: Inhibition of lymphocyte proliferation by the anti-arthritic drug sinomenine. Int J Immunopharmacol 16: 685-691, 1994. (Pubitemid 24238693)
8. Liu L, Buchner E, Beitze D, et al: Amelioration of rat experimental arthritides by treatment with the alkaloid sinomenine. Int J Immunopharmacol 18: 529-543, 1996. (Pubitemid 27105916)
9. Feng H, Yamaki K, Takano H, Inoue K, Yanagisawa R and Yoshino S: Effect of sinomenine on collagen induced arthritis in mice. Autoimmunity 40: 532-539, 2007. (Pubitemid 351233175)
10. Cheng Y, Zhang J, Hou W, et al: Immunoregulatory effects of sinomenine on the T-bet/GATA 3 ratio and Th1/Th2 cytokine balance in the treatment of mesangial proliferative nephritis. Int Immunopharmacol 9: 894-899, 2009.
11. Xu M, Liu L, Qi C, Deng B and Cai X: Sinomenine versus NSAIDs for the treatment of rheumatoid arthritis: a systematic review and meta analysis. Planta Med 74: 1423-1429, 2008.
12. Tong XM, Zhang J, Shen Y, Xie JJ and Jin J: Sinomenine enhanced aclarubicin-induced apoptosis by blocking NF kappa B pathway in HL 60 cells. J Med Plant Res 5: 635-643, 2011.
13. Li XJ, Yue PY, Ha WY, et al: Effect of sinomenine on gene expression of the IL 1 beta activated human synovial sarcoma. Life Sci 79: 665-673, 2006. (Pubitemid 43927979)
14. Jiang T, Zhou L, Zhang W, et al: Effects of sinomenine on proliferation and apoptosis in human lung cancer cell line NCI H460 in vitro. Mol Med Rep 3: 51-56, 2010.
15. Fan J, Wang JC, Chen Y, et al: Sinomenine induces apoptosis of prostate cancer cells by blocking activation of NF kappa B. African J Biotechnol 10: 3480-3487, 2011.
16. Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348, 2001. (Pubitemid 32467043)
17. Graña X and Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin dependent kinase inhibitors (CKIs). Oncogene 11: 211-219, 1995.
18. Loo DT and Rillema JR: Measurement of cell death. Methods Cell Biol 57: 251-264, 1998. (Pubitemid 128787444)
19. Budihardjo I, Oliver H, Lutter M, Luo X and Wang X: Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15: 269-290, 1999. (Pubitemid 32250377)
20. Jin Z and El Deiry WS: Overview of cell death signaling pathways. Cancer Biol Ther 4: 139-163, 2005. (Pubitemid 41351311)
21. Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194, 2005. (Pubitemid 40826487)
22. Adams JM and Cory S: The Bcl 2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998. (Pubitemid 28406819)
23. Slee EA, Adrain C and Martin SJ: Executioner caspase 3, -6 and -7 perform distinct, non redundant roles during the demolition phase of apoptosis. J Biol Chem 276: 7320-7326, 2001.
24. Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol 35: 495-516, 2007. (Pubitemid 46911891)
25. Delhalle S, Duvoix A, Schnekenburger M, Morceau F, Dicato M and Diederich M: An introduction to the molecular mechanisms of apoptosis. Ann NY Acad Sci 1010: 1-8, 2003. (Pubitemid 38264943)
26. Zeng J, Sun Y, Wu K, et al: Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria. Mol Cancer Ther 10: 104-116, 2011.
27. Lu XL, He SX, Ren MD, Wang YL, Zhang YX and Liu EQ: Chemopreventive effect of saikosaponin d on diethylinitrosamine induced hepatocarcinogenesis: Involvement of CCAAT/enhancer binding protein β and cyclooxygenase 2. Mol Med Rep 5: 637-644, 2012.
28. Oliver FJ, de la Rubia G, Rolli V, Ruiz Ruiz MC, de Murcia G and Murcia JM: Importance of poly(ADP ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 273: 33533-33539, 1998. (Pubitemid 29005737)
29. Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005, 2008.
30. Ito T, Shiraki K, Sugimoto K, et al: Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31: 1080-1085, 2000. (Pubitemid 30233232)
31. Shin S, Sung BJ, Cho YS, et al: An anti apoptotic protein human survivin is a direct inhibitor of caspase 3 and -7. Biochemistry 40: 1117-1123, 2001. (Pubitemid 32108606)
32. Tamm I, Wang Y, Sausville E, et al: IAP family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998. (Pubitemid 28551107)
33. Neugut AI: Aspirin as adjuvant therapy for colorectal cancer: a promising new twist for an old drug. JAMA 302: 688-689, 2009.
34. Jankowski JA and Limburg PJ: Aspirin therapy for cancer: it is never too late. Br J Cancer 105: 1105-1106, 2011.
35. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991. (Pubitemid 21917115)
36. Oda T, Tsuda H, Scarpa A, Sakamoto M and Hirohashi S: p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 52: 6358-6364, 1992.
37. Puisieux A, Galvin K, Troalen F, et al: Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J 7: 1407-1413, 1993. (Pubitemid 23336171)
38. Goldsmith KC and Hogarty MD: Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett 228: 133-141, 2005. (Pubitemid 41188435)
39. Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K and Takahashi R: A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 8: 613-621, 2001. (Pubitemid 32946938)
40. Hegde R, Srinivasula SM, Zhang Z, et al: Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein caspase interaction. J Biol Chem 277: 432-438, 2002. (Pubitemid 34952076)
41. Singh RP, Tyagi A, Sharma G, Mohan S and Agarwal R: Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down regulation of survivin. Clin Cancer Res 14: 300-308, 2008. (Pubitemid 351378006)
42. Katiyar SK, Roy AM and Baliga MS: Silymarin induces apoptosis primarily through a p53 dependent pathway involving Bcl 2/Bax, cytochrome c release and caspase activation. Mol Cancer Ther 4: 207-216, 2005. (Pubitemid 40340200)
43. Yang XD, Ai W, Asfaha S, et al: Histamine deficiency promotes inflammation associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells. Nat Med 17: 87-95, 2011.
44. Kok TW, Yue PY, Mak NK, Fan TP, Liu L and Wong RN: The anti angiogenic effect of sinomenine. Angiogenesis 8: 3-12, 2005.